{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-081982","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2024-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.842010+00:00","generated_at":"2026-05-31T01:39:57.751242+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pasithea reports positive Phase 1 data for PAS-004: no TRAEs, prolonged stable disease in colon cancer patient","bullets":["No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.","Heavily pre-treated stage 3 colon cancer patient (BRAF K601E) achieved prolonged stable disease, remains on drug into 6th cycle.","Half-life ~70 hours supports once-daily or less frequent oral dosing; steady-state Cmax/Cmin ratio of 1.2.","Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities.","Safety review completed; cohort 3 dosing initiated at 8 mg with protocol amendment to increase dosing schedule."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-081982","json":"https://secwatch.observer/filing/0001213900-24-081982.json","markdown":"https://secwatch.observer/filing/0001213900-24-081982.md","text":"https://secwatch.observer/filing/0001213900-24-081982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/0001213900-24-081982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/ea0215731-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:39:57.751242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}